Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | terminated | Phase 2 | 5 | Replimune, Inc.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT06739252 | Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA | terminated | Phase 2 | 1 | Peking UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | terminated | Phase 2 | 1 | Anwaar SaeedOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05987176 | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases(NELMAS) | terminated | Phase 2 | 1 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | terminated | Phase 2 | 19 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 21 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | terminated | Phase 2 | 6 | Chloe Atreya, MD, PhDOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04203160 | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | terminated | Phase 1 / Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | terminated | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | terminated | Phase 2 | 10 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | terminated | Phase 2 | 9 | Ludwig-Maximilians - University of MunichOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | terminated | Phase 2 | 4 | Lahey ClinicOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma(CLAUDIO-01) | terminated | Phase 1 / Phase 2 | 31 | SOTIO Biotech a.s.INDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 1 | BioNTech SEINDUSTRY | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract | terminated | Phase 2 | 13 | American Regent, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | terminated | Phase 2 | 13 | NYU Langone HealthOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | terminated | Phase 2 | 46 | Vall d'Hebron Institute of OncologyOTHER | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05350501 | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer(CLAUDE) | terminated | Phase 2 | 1 | EnteromeINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | terminated | Phase 2 | 47 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | terminated | Phase 2 | 180 | NuCana plcOTHER | 6 | Sep 12, 2025 | clinicaltrials |
| NCT00766142 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer(COCHISE) | terminated | Phase 2 | 18 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | terminated | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 7 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | terminated | Phase 2 | 18 | University Health Network, TorontoOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04579679 | Open-Label Surufatinib in European Patients With NET | terminated | Phase 2 | 78 | HutchmedINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT05619172 | A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer | terminated | Phase 2 | 16 | SOTIO Biotech AGINDUSTRY | 3 | Jul 24, 2025 | clinicaltrials |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | terminated | Phase 2 | 17 | Patrick BolandOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | terminated | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | terminated | Phase 2 | 6 | University of FloridaOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)(ELEVATE CRC) | terminated | Phase 2 | 77 | Gilead SciencesINDUSTRY | 10 | Jul 1, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 9, 2026source: clinicaltrials